Imago Pharmaceuticals logo

Imago Pharmaceuticals

Imago Pharmaceuticals, Inc. is a virtual company developing novel small molecule therapies for neurodegenerative, inflammatory and autoimmune diseases.

Imago was founded by the ex-scientific team of Elan Corporation. In 2013, Elan was acquired by Perrigo and later its JNK based preclinical research pipeline with a huge small molecule drug library, along with research tools were transferred to Imago.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.imago-pharma.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
435 Henley Rd, WY,83001-8799
Jackson State
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Imago is focused on developing small molecule inhibitors against stress-activated kinases. The Jun N-terminal kinase (JNK) has long been recognized as a promising target having potential disease-modifying activity in numerous diseases. Its preclinical programs includes small molecules targeting LRRK2, PLK2, BACE, Gamma-Secretase and AD Neurotoxicity.

In Sep. 2014, Imago acquired a portfolio of preclinical research assets, from Perrigo Company plc., the assets transferred also includes a 500,000 compound CNS-focused small-molecule library.

May 2016, Cure SMA has awarded a $300,000 drug discovery grant to Charlotte Sumner, MD, at Johns Hopkins University, in collaboration with Imago Pharmaceuticals for the Preclinical Development of a JNK Drug Candidate to Alter Disease Progression in SMA.

In May 2015, The Michael J. Fox Foundation for Parkinsons Research (MJFF) acquired the library of research tools around the parkin protein from Imago Pharmaceuticals. Mutations in the parkin (PARK2) gene are associated with young-onset Parkinsons disease and lead to dysfunction of the parkin protein.